BIOGEN INC
For the period ended Sep 30, 2024. Filed Oct 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 30, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
ISSUER PURCHASES OF EQUITY SECURITIES
The following table summarizes our common stock repurchase activity under our 2020 Share Repurchase Program during the third quarter of 2024:
| Period | Total Number ofShares Purchased(#) | Average PricePaid per Share($) | Total Number ofShares Purchasedas Part of PubliclyAnnounced Programs(#) | Approximate Dollar Valueof Shares That May Yet Be Purchased UnderOur Programs($ in millions) |
|---|---|---|---|---|
| July 1, 2024 - July 31, 2024 | — | $— | — | $2,050.0 |
| August 1, 2024 - August 31, 2024 | — | $— | — | $2,050.0 |
| September 1, 2024 - September 30, 2024 | — | $— | — | $2,050.0 |
| Total(1) | — | $— | ||
(1)There were no share repurchases during the third quarter of 2024.
In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and nine months ended September 30, 2024 and 2023. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.